Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 846 participants.

Also called NCT07508618

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 846 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07508618
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07508618. Randomized; quadruple masking; primary purpose prevention. Start 2026-02-09 (actual); primary completion 2027-08-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study on the Prevention of Atrial Fibrillation Recurrence After Ablation by Qidong Yixin Granule
Acronym
QDYX-AF
Condition
Persistent Atrial Fibrillation
Intervention (Drug)
Qi Dong Yi Xin Granules
Intervention (Drug)
Placebo
Lead sponsor
Sir Run Run Shaw Hospital (class: other)
Collaborator
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07508618
Content hash
76f5d1a6c1160d42e4bb1b45a22ee17fa2910d0ee6350b6f56e22af938b43a34